查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081449

氣喘治療市場：2026-2032年全球市場預測（依產品類型、藥物類別、給藥途徑、疾病類型、最終用戶和分銷管道分類）

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Disease Type, End Users, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，氣喘治療市場將成長至 396.2 億美元，複合年成長率為 6.34%。

主要市場統計數據
基準年 2025 257.5億美元
預計年份：2026年 273.1億美元
預測年份 2032 396.2億美元
複合年成長率 (%) 6.34%

氣喘治療市場概覽

氣喘是世界上最常見的慢性疾病之一，氣喘藥物在呼吸系統疾病治療中仍然佔據核心地位。根據世界衛生組織（世衛組織）統計，2019年全球約有2.62億人患有氣喘，約45.5萬人死於氣喘。可預防的氣喘高發生區集中在診斷、吸入性糖皮質激素和專科護理不足的地區。因此，氣喘藥物市場既是維持治療領域用量龐大的藥品類別，也是精準醫療領域的成長點。

氣喘藥物領域的變革性變化

氣喘藥物治療的趨勢正從緩解症狀轉向降低風險、預防急性發作和基於表現型的治療。雖然吸入性糖皮質激素療法仍然是治療的基礎，但聯合吸入藥物以及結合維持治療和安寧療護的治療方案正日益受到重視，因為與單獨使用安寧療護藥物的治療模式相比，它們能夠降低急性發作的風險。

人工智慧對氣喘治療的累積影響

人工智慧（AI）正日益成為氣喘治療各領域的一股重要驅動力，涵蓋藥物發現、臨床開發、診斷、用藥依從性以及上市後監測等各個面向。在研發領域，人工智慧模型正協助辨識發炎路徑、進行表現型患者分層，並檢驗重症氣喘及其他相關呼吸道疾病的治療標靶。

關於氣喘藥物的關鍵區域性見解

亞太地區氣喘治療市場成長迅速，這主要得益於其龐大的患者群體、快速的都市化、工業空氣污染、菸草暴露以及不斷擴大的醫療保險覆蓋範圍。中國、印度、日本、韓國和澳洲各自擁有不同的需求領域，涵蓋了吸入性皮質類固醇和聯合治療的廣泛應用，以及在專科醫療機構中引入先進生物製藥等。

關於氣喘藥物的關鍵群體特定見解

在東協市場，對都市區空氣品質的關注、對兒童呼吸系統疾病日益成長的認知以及保險覆蓋範圍的擴大，都推動了吸入維持治療的需求，進而促進了市場擴張。然而，由於價格高度敏感且獲取途徑分散，價格適中的吸入型皮質類固醇和固定劑量組合藥物對於市場滲透至關重要。

各國氣喘藥物關鍵資訊分析

美國擁有大規模的專家網路和保險公司資料庫，是氣喘生物製劑、複方吸入劑和病患支持計畫的核心市場。在加拿大，基於指南的用藥途徑和成本效益備受重視；而墨西哥和巴西預計將迎來顯著的銷售量成長，這得益於價格合理的維持治療藥物以及基層醫療診斷能力的提升。

為氣喘治療產業的領導者提供的實用建議

由於可預防的氣喘急性發作仍造成巨大的臨床和經濟負擔，業界領導者應優先考慮廣泛提供治療方案，包括吸入型皮質類固醇。產品組合策略應平衡價格合理的學名藥、差異化的複方吸入劑以及用於治療重度氣喘的生物製藥，從而同時滿足高銷售量和高價值的市場需求。

調查方法

本執行摘要採用系統化的二手調查方法編寫，並參考了經檢驗的公共衛生、監管、臨床和市場情報資訊來源。主要資訊來源包括世界衛生組織 (WHO) 的疾病負擔數據、全球氣喘舉措(GINA) 的最新治療策略、各國衛生機構的統計數據、法規核准趨勢、同行評審的呼吸醫學文獻以及來自真實世界氣喘管理項目的證據。

結論

氣喘治療市場正朝著更加一體化的護理模式轉型，該模式融合了以控制藥物為主的療法、精準生物製藥、數位化用藥依從性管理以及注重永續性的吸入器創新。全球氣喘負擔沉重，以及持續減少氣喘急性發作、急診就診和可預防死亡的需求，都持續支撐著市場對氣喘治療的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章氣喘治療市場：依產品類型分類

  • 吸入器
  • 噴霧器
    • 噴射式霧化器
    • 超音波霧化器
    • 篩孔式噴霧器
  • 口服藥物
    • 藥片
    • 膠囊
    • 糖漿
  • 注射藥物

第8章：氣喘治療市場：依藥物類別分類

  • 沙丁胺醇
  • BETA-激動劑
  • 支氣管擴張劑
  • 皮質類固醇
  • 白三烯調節劑

第9章：氣喘治療市場：依給藥方式分類

  • 吸入劑
  • 口服

第10章：氣喘治療市場：依疾病類型分類

  • 過敏性氣喘
  • 非過敏性氣喘

第11章：氣喘治療市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院和診所

第12章：氣喘治療市場：依通路分類

  • 線上
  • 離線

第13章：氣喘治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章氣喘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：氣喘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • Dr.Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Lallemand Inc.
  • Merck KGaA
  • Mundipharma International Limited
  • NIOX Group PLC
  • Novartis AG
  • Novo Holdings
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanner GmbH
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • Viatris, Inc.
Product Code: MRR-434CCDA05226

The Asthma Drugs Market is projected to grow by USD 39.62 billion at a CAGR of 6.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 25.75 billion
Estimated Year [2026] USD 27.31 billion
Forecast Year [2032] USD 39.62 billion
CAGR (%) 6.34%

Asthma Drugs Market Introduction

Asthma drugs remain central to respiratory care because asthma is one of the world's most common chronic diseases. The World Health Organization reported that asthma affected about 262 million people in 2019 and caused approximately 455,000 deaths, with preventable morbidity concentrated where diagnosis, inhaled corticosteroids, and specialist care are inconsistent. This makes the asthma therapeutics market both a high-volume maintenance category and a precision-medicine growth segment.

The market spans inhaled corticosteroids, long-acting beta agonists, leukotriene receptor antagonists, long-acting muscarinic antagonists, short-acting relievers, fixed-dose inhaler combinations, and injectable biologics. Current clinical practice is increasingly aligned with Global Initiative for Asthma guidance that prioritizes inhaled corticosteroid-containing therapy and discourages reliance on short-acting bronchodilator-only treatment for adults and adolescents.

Growth is being shaped by rising respiratory disease awareness, air pollution exposure, aging populations, pediatric asthma management, biologic adoption for severe asthma, and the expansion of digital inhaler ecosystems. At the same time, pricing pressure, generic competition, inhaler sustainability requirements, and unequal access to essential asthma medicines are redefining commercial strategy.

Transformative Shifts in the Asthma Drugs Landscape

The asthma drugs landscape is shifting from symptom relief toward risk reduction, exacerbation prevention, and phenotype-guided care. Inhaled corticosteroid-based regimens remain the foundation of treatment, while combination inhalers and maintenance-and-reliever approaches are gaining clinical relevance because they reduce exacerbation risk compared with reliever-only patterns.

Severe asthma is undergoing the most visible transformation. Biologics targeting IgE, IL-5, IL-5 receptor, IL-4 receptor alpha, and TSLP have moved treatment beyond broad anti-inflammatory control toward biomarker-informed prescribing. Blood eosinophils, fractional exhaled nitric oxide, allergy status, oral corticosteroid dependence, and exacerbation history now influence therapy selection and payer authorization.

The competitive environment is also changing through device innovation, generic inhaler approvals, value-based contracting, and environmental policy. Regulators and health systems are scrutinizing hydrofluorocarbon-based metered dose inhalers, while dry powder inhalers, soft mist inhalers, propellant reformulation, and recycling programs are becoming strategic differentiators.

Cumulative Impact of Artificial Intelligence on Asthma Therapeutics

Artificial intelligence is becoming a practical accelerator across asthma drug discovery, clinical development, diagnosis, adherence, and post-market surveillance. In research, AI models help identify inflammatory pathways, stratify patients by phenotype, and support target validation for severe asthma and overlapping respiratory conditions.

In clinical development, machine learning can improve trial design by identifying high-risk patients, predicting exacerbation patterns, and reducing screen failures in biomarker-defined studies. Real-world evidence platforms using electronic health records, claims data, spirometry, wearable data, and smart inhaler use can help evaluate medication persistence, inhaler technique, and health-system outcomes.

Commercially, AI-enabled patient support tools can detect poor adherence, forecast refill gaps, and personalize education. The most credible use cases will require transparent algorithms, privacy protection, clinically validated endpoints, and careful mitigation of bias, particularly because asthma outcomes are strongly influenced by housing, pollution exposure, income, and access to care.

Key Regional Insights for Asthma Drugs

Asia-Pacific is a high-growth region for asthma drugs because of large patient populations, rapid urbanization, industrial air pollution, tobacco exposure, and expanding healthcare coverage. China, India, Japan, South Korea, and Australia represent distinct demand pools, ranging from high-volume inhaled corticosteroid and combination therapy use to advanced biologic uptake in specialist centers.

North America remains a leading region for branded biologics, advanced inhaler combinations, payer-managed formularies, and digital respiratory care. The United States has a large diagnosed asthma population and strong specialty prescribing infrastructure, while Canada's public-private reimbursement environment supports evidence-based access but requires careful health technology assessment alignment.

Latin America shows growing demand for affordable controller medicines, especially in Brazil and Mexico, where urban pollution and healthcare access gaps shape asthma outcomes. Europe is characterized by robust clinical guidelines, regulatory maturity, biosimilar and generic competition, and heightened attention to low-carbon inhaler policy. The Middle East faces asthma triggers linked to dust, heat, smoking, and urban development, while Africa's market is constrained by underdiagnosis, limited spirometry access, and inconsistent availability of inhaled corticosteroids, creating significant public health opportunity.

Key Group Insights for Asthma Drugs

ASEAN markets are expanding as urban air quality concerns, pediatric respiratory disease awareness, and broader insurance coverage support demand for inhaled maintenance therapy. However, pricing sensitivity and fragmented access make affordable inhaled corticosteroids and fixed-dose combinations critical to market penetration.

The GCC represents a premium respiratory care environment with strong hospital infrastructure, high specialist access in major cities, and demand for severe asthma biologics. Environmental triggers, including dust storms and high particulate exposure, reinforce the need for prevention-focused asthma management and adherence support.

The European Union influences global asthma drug strategy through centralized regulatory pathways, pharmacovigilance standards, environmental policy, and health technology assessment. BRICS countries combine large patient volumes with local manufacturing ambitions, making cost-effective inhalers, generics, and selective biologic access essential. G7 markets drive innovation adoption through advanced reimbursement systems and real-world evidence expectations, while NATO-aligned healthcare systems emphasize supply continuity, medicine security, and resilient procurement for essential respiratory drugs.

Key Country Insights for Asthma Drugs

The United States is a core market for asthma biologics, combination inhalers, and patient support programs, supported by specialist networks and large payer databases. Canada emphasizes guideline-based access and cost-effectiveness, while Mexico and Brazil offer substantial volume opportunities for affordable controllers and improved diagnosis in primary care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature respiratory guidelines with payer scrutiny and growing environmental pressure on inhaler selection. Germany and France are important for evidence-driven reimbursement, the United Kingdom is influential in severe asthma pathways and low-carbon prescribing, and Italy and Spain remain significant markets for fixed-dose inhaled therapies. Russia presents demand for essential asthma medicines but faces access and supply-chain complexity.

Across Asia-Pacific, China and India are high-volume markets where urban pollution, expanding insurance coverage, and local manufacturing shape growth. Japan and South Korea show strong uptake of innovative therapies and digital health integration, while Australia has advanced respiratory guidelines and high awareness of preventable exacerbations. Together, these countries define the competitive balance between affordability, innovation, and outcomes-based care.

Actionable Recommendations for Asthma Drug Industry Leaders

Industry leaders should prioritize broad access to inhaled corticosteroid-containing therapy because preventable exacerbations remain a major clinical and economic burden. Portfolio strategies should balance affordable generics, differentiated combination inhalers, and biologics for severe asthma to capture both high-volume and high-value segments.

Companies should strengthen biomarker-enabled pathways for biologics by investing in evidence around eosinophils, FeNO, allergy status, exacerbation reduction, oral corticosteroid sparing, and quality-of-life improvement. Payer engagement must be supported by real-world outcomes, adherence data, and clear patient selection criteria.

Leaders should also prepare for environmental requirements by advancing low-carbon inhaler options, propellant transitions, device lifecycle programs, and patient education that preserves clinical effectiveness. Digital inhaler partnerships, AI-enabled adherence tools, and integrated respiratory platforms can improve differentiation when backed by validated outcomes and privacy-by-design systems.

Research Methodology

This executive summary is developed using a structured secondary research methodology supported by validated public health, regulatory, clinical, and market intelligence sources. Core inputs include World Health Organization disease burden data, Global Initiative for Asthma treatment strategy updates, national health agency statistics, regulatory approval trends, peer-reviewed respiratory medicine literature, and evidence from real-world asthma management programs.

The analysis triangulates disease prevalence, treatment guidelines, product class dynamics, reimbursement factors, regional access patterns, and emerging technology signals. Qualitative assessment is applied to competitive positioning, biologic adoption, inhaler-device trends, sustainability policy, and AI-enabled care models.

All insights are reviewed for consistency with verified industry evidence and framed for executive decision-making. The methodology avoids unsupported market-size claims and emphasizes trends that are observable through clinical guidelines, regulatory activity, payer behavior, epidemiology, and healthcare infrastructure development.

Conclusion

The asthma drugs market is moving toward a more integrated model of care that combines controller-first treatment, precision biologics, digital adherence, and sustainability-oriented inhaler innovation. Demand remains supported by the large global asthma burden and the continued need to reduce exacerbations, emergency visits, and avoidable deaths.

Competitive success will depend on delivering measurable outcomes across diverse healthcare systems. Organizations that expand access to essential controller medicines, build differentiated severe asthma portfolios, validate AI-enabled tools, and align with environmental policy will be best positioned for long-term growth.

Asthma therapeutics will continue to evolve from a product-centered market into an outcomes-centered ecosystem, where clinical evidence, affordability, device usability, and patient engagement determine leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Asthma Drugs Market, by Product Type

  • 7.1. Inhalers
  • 7.2. Nebulizers
    • 7.2.1. Jet Nebulizers
    • 7.2.2. Ultrasonic Nebulizers
    • 7.2.3. Mesh Nebulizers
  • 7.3. Oral drugs
    • 7.3.1. Tablets
    • 7.3.2. Capsules
    • 7.3.3. Syrups
  • 7.4. Injectable

8. Asthma Drugs Market, by Drug Class

  • 8.1. Albuterol
  • 8.2. Beta Agonists
  • 8.3. Brochodilators
  • 8.4. Corticosteroids
  • 8.5. Leukotriene Modifiers

9. Asthma Drugs Market, by Delivery Mode

  • 9.1. Inhalable
  • 9.2. Oral

10. Asthma Drugs Market, by Disease Type

  • 10.1. Allergic Asthma
  • 10.2. Non-allergic Asthma

11. Asthma Drugs Market, by End Users

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals & Clinics

12. Asthma Drugs Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Asthma Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Asthma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. ALK-Abello A/S
  • 17.2. Amphastar Pharmaceuticals, Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Bayer AG
  • 17.5. Boehringer Ingelheim International GmbH
  • 17.6. CHIESI Farmaceutici S.p.A.
  • 17.7. Cipla Limited
  • 17.8. Dr.Reddy's Laboratories Ltd
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. GlaxoSmithKline PLC
  • 17.11. Hetero Labs Limited
  • 17.12. Lallemand Inc.
  • 17.13. Merck KGaA
  • 17.14. Mundipharma International Limited
  • 17.15. NIOX Group PLC
  • 17.16. Novartis AG
  • 17.17. Novo Holdings
  • 17.18. OPKO Health, Inc.
  • 17.19. Pfizer Inc.
  • 17.20. Sanner GmbH
  • 17.21. Sanofi S.A.
  • 17.22. Sunovion Pharmaceuticals Inc.
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Verona Pharma PLC
  • 17.25. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ASTHMA DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ASTHMA DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ASTHMA DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JET NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JET NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JET NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MESH NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MESH NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MESH NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALBUTEROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALBUTEROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALBUTEROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BETA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BETA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BROCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BROCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BROCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INHALABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 320. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 321. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)